648 related articles for article (PubMed ID: 33239231)
1. Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.
Bai X; Hippensteel J; Leavitt A; Maloney JP; Beckham D; Garcia C; Li Q; Freed BM; Ordway D; Sandhaus RA; Chan ED
Med Hypotheses; 2021 Jan; 146():110394. PubMed ID: 33239231
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
[TBL] [Abstract][Full Text] [Related]
3. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
4. d-Galactose treatment increases ACE2, TMPRSS2, and FURIN and reduces SERPINA1 mRNA expression in A549 human lung epithelial cells.
Baristaite G; Gurwitz D
Drug Dev Res; 2022 May; 83(3):622-627. PubMed ID: 34677831
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 mutation 614G creates an elastase cleavage site enhancing its spread in high AAT-deficient regions.
Bhattacharyya C; Das C; Ghosh A; Singh AK; Mukherjee S; Majumder PP; Basu A; Biswas NK
Infect Genet Evol; 2021 Jun; 90():104760. PubMed ID: 33556558
[TBL] [Abstract][Full Text] [Related]
6. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Gupta VK; Murthy MK; Patil S
Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
8. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections.
Rosendal E; Mihai IS; Becker M; Das D; Frängsmyr L; Persson BD; Rankin GD; Gröning R; Trygg J; Forsell M; Ankarklev J; Blomberg A; Henriksson J; Överby AK; Lenman A
mBio; 2022 Jun; 13(3):e0089222. PubMed ID: 35532162
[TBL] [Abstract][Full Text] [Related]
9. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
10. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.
Jonigk D; Al-Omari M; Maegel L; Müller M; Izykowski N; Hong J; Hong K; Kim SH; Dorsch M; Mahadeva R; Laenger F; Kreipe H; Braun A; Shahaf G; Lewis EC; Welte T; Dinarello CA; Janciauskiene S
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):15007-12. PubMed ID: 23975926
[TBL] [Abstract][Full Text] [Related]
12. Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence.
Bai X; Schountz T; Buckle AM; Talbert JL; Sandhaus RA; Chan ED
Biochem Soc Trans; 2023 Jun; 51(3):1361-1375. PubMed ID: 37294003
[TBL] [Abstract][Full Text] [Related]
13. Diacerein: A potential multi-target therapeutic drug for COVID-19.
de Oliveira PG; Termini L; Durigon EL; Lepique AP; Sposito AC; Boccardo E
Med Hypotheses; 2020 Nov; 144():109920. PubMed ID: 32534337
[TBL] [Abstract][Full Text] [Related]
14. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
Mahoney M; Damalanka VC; Tartell MA; Chung DH; Lourenço AL; Pwee D; Mayer Bridwell AE; Hoffmann M; Voss J; Karmakar P; Azouz NP; Klingler AM; Rothlauf PW; Thompson CE; Lee M; Klampfer L; Stallings CL; Rothenberg ME; Pöhlmann S; Whelan SPJ; O'Donoghue AJ; Craik CS; Janetka JW
Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34635581
[TBL] [Abstract][Full Text] [Related]
15. Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro.
Raghavan PR
Biomed Res Int; 2022; 2022():1558860. PubMed ID: 35039793
[TBL] [Abstract][Full Text] [Related]
16. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
[TBL] [Abstract][Full Text] [Related]
17. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Sallenave JM; Guillot L
Front Immunol; 2020; 11():1229. PubMed ID: 32574272
[TBL] [Abstract][Full Text] [Related]
18. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
19. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
Beeraka NM; Sadhu SP; Madhunapantula SV; Rao Pragada R; Svistunov AA; Nikolenko VN; Mikhaleva LM; Aliev G
Front Immunol; 2020; 11():552925. PubMed ID: 33072093
[TBL] [Abstract][Full Text] [Related]
20. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
